Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -168K | 0 | 0 | 0 | 0 |
| Operating Income | -103M | -98M | -99M | -119M | -92M |
| EBITDA | -97M | -98M | -99M | -86M | -92M |
| Net Income | -97M | -101M | -94M | -120M | -93M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$14.86
+1.02% today
1Y Change
+102.57%
Window
Jun 25, 2025 → Jun 18, 2026
Coverage: 247 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immunic, Inc. (IMUX) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $14.86 and up 102.6% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.6%, free cash flow -1.1% with operating margin 0.0% and ROIC 1693.4%. Stock Foundry combines IMUX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMUX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMUX Max Drawdown
-54.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for IMUX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$92.9M
+22.8% YoY
Free Cash Flow
-$83.3M
-27.7% YoY
Revenue Growth
+0.0%
EPS Growth
+37.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -168K | 0 | 0 | 0 | 0 |
| Operating Income | -103M | -98M | -99M | -119M | -92M |
| EBITDA | -97M | -98M | -99M | -86M | -92M |
| Net Income | -97M | -101M | -94M | -120M | -93M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15M | 36M | 47M | 107M | 87M |
| Total Assets | 24M | 41M | 54M | 128M | 139M |
| Total Liabilities | 31M | 22M | 25M | 14M | 12M |
| Shareholder Equity | -7M | 18M | 29M | 114M | 127M |
| Total Debt | 684K | 1M | 1M | 2M | 992K |
| Net Debt | -15M | -35M | -45M | -105M | -86M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
83M
-27.8% YoY
Capital Expenditures
67K
+40.2% YoY
Free Cash Flow
83M
-27.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1197.8%
Debt / Equity
-0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.